flow trial semaglutide kidney outcomes ❇️Patients with obesity, type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. This study, the now published, evaluated treatment with (# FLOW trial Ozempic® (semaglutide injection)

Cutrullis, R

Improvements in cardiometabolic risk factors by weight reduction: a post hoc analysis of adults with obesity randomly assigned to tirzepatide

According to a May 2025 WHO report, 2.5 billion adults worldwide were overweight in 2022, including 890 million having obesity

The change in Blue Cross Blue Shield GLP-1 coverage excludes those drugs from insurance coverage for members who seek to lose weight and whose employers are enrolled in our fully insured commercial health plans

Its Informative and FREE

A comparison of the pattern of intracellular carnitine and its derivatives in PBMC and erylysate, as well as between both groups, revealed notable differences